BASFY vs BCPC: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BASFY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BASFY and BCPC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BASFY and BCPC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

BASF SE, headquartered in Ludwigshafen, Germany, is the largest chemical producer in the world by sales, with group revenue of about €59.7 billion in 2025. It makes the building blocks of modern industry: basic chemicals and petrochemicals from its integrated Verbund sites, engineering plastics and polyurethanes, battery and catalyst materials, nutrition and personal care ingredients, and crop protection products and seeds through its Agricultural Solutions division. The Verbund model, in which plants at a single site feed each other's by-products and energy, is the company's core competitive idea, and Ludwigshafen is the largest integrated chemical complex on earth. In 2025 BASF started up the main plants at a new Verbund site in Zhanjiang, China, a roughly €8.7 billion bet that the world's biggest chemical market will keep growing. The US-traded BASFY is a sponsored Level I ADR on OTCQX, with BNY Mellon as depositary and four ADRs representing one ordinary share listed on Xetra under the ticker BAS.

Full BASFY guide

Balchem Corporation is a specialty ingredients company organized into three segments: Human Nutrition and Health (choline nutrients, encapsulated ingredients, flavor and food systems), Animal Nutrition and Health (microencapsulated feed additives, chelated minerals, and choline chloride for livestock and pets), and Specialty Products (ethylene-oxide sterilization for medical devices, plus fumigants for food safety). It is a leader in choline chemistry and microencapsulation, selling into food, beverage, dietary supplement, animal feed, and healthcare end markets that tend to hold up through economic cycles.

Full BCPC guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BASFY drivers: Earnings recovery and raised 2026 guidance; Portfolio reshaping: coatings out, agriculture toward an IPO.
• BCPC drivers: Human Nutrition and Health momentum; Specialty Products and medical sterilization.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: BASF is a cyclical company, and chemical prices, volumes and margins can turn quickly with industrial production, construction and auto demand, so a strong quarter can reverse within a year. For BCPC, balchem trades at a premium earnings multiple (about 34x trailing and 27x forward as of October 2026), so any slowdown in growth or margin pressure could compress the valuation meaningfully.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BASFY if you believe its drivers more; BCPC if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BASFY and BCPC guides.

BASFY. BASF shares traded around €53 in early autumn 2026, which puts the ADR in the mid-teens in dollars given the four-for-one ratio. On the guided 2026 EBITDA before special items, the stock trades at a mid-single-digit EV/EBITDA multiple once net debt and pensions are added back, which is typical for European commodity-heavy chemical producers and cheaper than US specialty peers. Reported net income in 2026 is inflated by the roughly €3.9 billion coatings disposal gain, so trailing P/E figures quoted on data sites can look misleadingly low and are best read alongside the underlying EBITDA trend.

BCPC. Balchem posted record second-quarter 2026 net sales of about $284 million, up roughly 11% year over year, and adjusted EPS of $1.49 ahead of estimates, extending its streak of year-over-year adjusted EBITDA growth to 28 quarters. At $170.80 the stock trades at about 34x trailing and 27x forward earnings and about 20x EV/EBITDA, a multiple that prices in continued consistency. Q3 results arrive October 23, 2026, with consensus near $1.53 per share.

Headline figures (approximate, October 2026): BASFY shows revenue (fy 2025) ~€59.7B (~$69B), ebitda before special items (fy 2025) ~€6.6B, 2026 ebitda before special items guidance €6.9B to €7.7B (raised in July), q2 2026 sales / ebitda bsi ~€17.2B / ~€2.4B; BCPC shows revenue (ttm) ~$1.09B (Q2 2026 up ~11% YoY), net income (ttm) ~$164M (net margin ~15%), q2 2026 net sales ~$284M (record), q2 2026 adjusted eps ~$1.49 vs ~$1.42 estimate.

BASFY and BCPC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BASFY and BCPC exposure against your real portfolio. It is not an investment adviser.